Macular degeneration is a serious retinal disease that can easily cause blindness. The common clinical causes include age-related, highly myopic, idiopathic, and inflammatory, traumatic, and tumor-derived; the first three are the most common. The clinical symptoms are painless blurred vision, distorted vision, and distortion, mostly in one eye, but can also occur in both eyes or at the same time. The signs are: decreased visual acuity, hemorrhage, edema and exudation in the macula of the eye. Ancillary tests: Fundus fluorescence angiography (FFA): fluorescein leakage. Optical coherence scan (OCT ) shows choroidal neovascularization (CNV) growth. Treatment: poor healing of the natural course of the disease. Macular degeneration is divided into a dry phase and a wet phase according to the progression of the disease. Medication in the dry phase includes antioxidant vitamins and mineral supplements, and requires regular follow-up examinations. The wet phase is characterized by recurrent bleeding and scarring of the macula, and eventual loss of central vision if not treated aggressively. However, for wet macular degeneration, the effect of common drug treatment is poor. With the continuous improvement of ophthalmology treatment technology in China, and in line with the world’s advanced frontier technology, and mastering the latest international concept of macular degeneration treatment, photodynamic therapy (PDT) and combined with rezumab injection are currently used for wet macular degeneration, bringing hope to patients suffering from macular degeneration who are plagued by blindness to regain their sight. Photodynamic therapy is performed by intravenous injection of a photosensitizer, and the application of a specific wavelength of laser excitation causes the photosensitizer to bind to the neovascularization for the purpose of closing the neovascularization. Mechanism of action of Ranibizumab: Inhibit choroidal neovascularization (CNV) and reduce bleeding and leakage through specific anti-VEGF. Route of administration: vitreous cavity injection. Duration of treatment: Repeat injection is possible according to the effect of the initial treatment and follow-up and examination, and the condition requires. Treatment can be given alone or in combination according to different clinical manifestations. If the fundus is not thick, photodynamic therapy can be administered, and if not, vitreous humor injection can be given first and then combined with photodynamic therapy. Usually combined with fundus manifestations and angiography and OCT examination, we can flexibly choose the treatment mode to achieve the best treatment effect.